Medicine - Nephrology

Medicine & Life Sciences

1. Kidney 100%
2. Chronic Renal Insufficiency 57%
3. Podocytes 51%
4. Kidney Diseases 36%
5. Acute Kidney Injury 33%
6. Transplants 32%
7. Diabetic Nephropathies 32%
8. Allografts 31%
9. Advanced Glycation End Products 30%
10. Dialysis 26%
11. Renal Dialysis 26%
12. WW Domains 25%
13. Wounds and Injuries 24%
14. Transplant Recipients 24%
15. T-Lymphocytes 23%
16. Genes 22%
17. Proteins 20%
18. Kidney Transplantation 20%
19. Coronavirus 19%
20. Biomarkers 18%
21. Chronic Kidney Failure 18%
22. Genome-Wide Association Study 17%
23. Genome 17%
24. Glomerular Filtration Rate 16%
25. AIDS-Associated Nephropathy 16%
26. Meta-Analysis 16%
27. Inflammation 15%
28. Organ Transplantation 14%
29. Type 2 Diabetes Mellitus 14%
30. Creatinine 14%
31. Mortality 14%
32. Serum 14%
33. Therapeutics 14%
34. Electronic Health Records 13%
35. Tissue Donors 13%
36. Population 13%
37. Transplantation 13%
38. Focal Segmental Glomerulosclerosis 13%
39. SARS Virus 12%
40. Renal Insufficiency 12%
41. Nephrology 12%
42. Fibrosis 11%
43. Blood Pressure 11%
44. HIV 11%
45. Diet 11%
46. Epithelial Cells 11%
47. Autosomal Dominant Polycystic Kidney 11%
48. Hypertension 10%
49. Proteinuria 10%
50. Albuminuria 10%
51. Peritoneal Dialysis 10%
52. Phenotype 9%
53. Cardiovascular Diseases 9%
54. African Americans 9%
55. Endothelial Cells 9%
56. Confidence Intervals 9%
57. Disease Progression 9%
58. Biopsy 9%
59. Apoptosis 9%
60. Polycystic Kidney Diseases 8%
61. Genomics 8%
62. Immunosuppression 8%
63. Phosphorus 8%
64. Gene Expression 8%
65. polycystic kidney disease 1 protein 8%
66. Ligands 8%
67. Nephrons 8%
68. Health 8%
69. HIV-1 8%
70. Urine 8%
71. Antibodies 8%
72. Large-Conductance Calcium-Activated Potassium Channels 8%
73. Oxidative Stress 8%
74. Exome 7%
75. Receptor for Advanced Glycation End Products 7%
76. Messenger RNA 7%
77. Cohort Studies 7%
78. Immunosuppressive Agents 7%
79. Thoracic Surgery 7%
80. Heart Failure 7%
81. Phosphorylation 7%
82. Clinical Trials 7%
83. Immunity 7%
84. Cilia 7%
85. Critical Illness 7%
86. Renal Replacement Therapy 7%
87. Odds Ratio 7%
88. Randomized Controlled Trials 6%
89. Regulatory T-Lymphocytes 6%
90. Liver Transplantation 6%
91. Transforming Growth Factors 6%
92. N(6)-carboxymethyllysine 6%
93. Hospitalization 6%
94. Macrophages 6%
95. Precision Medicine 6%
96. Graft Survival 6%
97. Single Nucleotide Polymorphism 6%
98. In Vitro Techniques 6%
99. B-Lymphocytes 6%
100. Albumins 6%